Epidemiology of Lung Cancer: Implications for screening and prevention

Hormuzd A. Katki, Ph.D.

Senior Investigator
Division of Cancer Epidemiology and Genetics (DCEG)

I thank my DCEG colleagues Neil Caporaso and Neal Freedman for sharing slides with me
Cancer Death Rates* Among Men, US, 1930-2005

*Age-adjusted to the 2000 US standard population.
Cancer Death Rates* Among Women, US, 1930-2005

Rate Per 100,000

*Age-adjusted to the 2000 US standard population.
Smoking prevalence in US men and women

Burns et al, NCI Smoking and Tobacco Control Monograph No. 8, 1997
Haven’t cigarettes gotten safer?

People changed the way they smoke

- Increased number of puffs
- Increased puff volume
- Increased inhalation depth
Changing distribution of lung cancer histologic types over time

Rate per 100,000 person-years

Years


Rate per 100,000 person-years

SEER-9 cancer registries, Cook M et al, CEBP, 2009
New and emerging tobacco products
Marijuana
Lung cancer relative risk drops after quitting smoking, but ...

20+ year quitters still have double the lung-cancer risk of non-smokers
Lung-cancer death risk plateaus after quitting smoking

- Don’t just quit, quit **AS YOUNG AS POSSIBLE**
- Most lung cancer in the US is in **former smokers**!

Halperin, JNCI, 1993; Peto J, Br J Cancer 2011
Slightly more quitting among those with major abnormalities found by CT lung screening?

Background
National Lung Screening Trial (NLST)

- NLST participants: ages 55-74, ≥30 pack-years, ≤15 quit-years
- 3 CT screens reduced lung cancer death by 20%
Background: USPSTF and CMS

- USPSTF guidelines
  - ages 55-80, ≥30 pack-years, ≤15 quit-years

- CMS reimbursement guideline
  - ages 55-77, ≥30 pack-years, ≤15 quit-years

de Koning et al, Ann Int Med, 2014
USPSTF calls for improved risk assessment tools for screening

• In response to public comments that lung screening be restricted to those at highest risk, the USPSTF stated:

“The USPSTF acknowledges the importance of accurately identifying persons who are at highest risk to maximize the benefits and minimize the harms of screening and calls for more research to improve risk assessment tools.”

Final Recommendation Statement: Lung Cancer Screening, USPSTF, 2013
Lung cancer death model

- Risk factors
  - self-reported
  - well-known

- Log(age): HR=431

- Continuous
  - Age
  - Smoke years
  - Quit years
  - BMI

Katki, ... Chaturvedi, JAMA, 2016
Risk-based selection may be more effective and efficient than current guidelines

<table>
<thead>
<tr>
<th></th>
<th>USPSTF-eligible smokers</th>
<th>Risk-based: Fixed-USPSTF population size</th>
<th>% gain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of eligible smokers (% ever-smokers screened)</td>
<td>9,018,130 (21%)</td>
<td>9,018,693 (21%)</td>
<td></td>
</tr>
<tr>
<td>5-year lung-cancer risk threshold</td>
<td>-</td>
<td>1.9%</td>
<td></td>
</tr>
<tr>
<td>Number of preventable lung-cancer deaths (% of preventable lung-cancer deaths)</td>
<td>46,488 (57%)</td>
<td>55,717 (68%)</td>
<td>20%</td>
</tr>
<tr>
<td>Effectiveness: Number needed to screen (NNS) to prevent 1 lung-cancer death</td>
<td>194</td>
<td>162</td>
<td>17%</td>
</tr>
<tr>
<td>Efficiency: # of false-positive screens per prevented lung-cancer death</td>
<td>133</td>
<td>116</td>
<td>13%</td>
</tr>
</tbody>
</table>

Katki, ... Chaturvedi, JAMA, 2016
Projected outcomes from risk-based CT lung cancer screening

<table>
<thead>
<tr>
<th>Screened Ever-Smokers Aged 50-80 y, millions</th>
<th>Preventable Lung Cancer Deaths Over 5 y, %</th>
<th>No. of prevented deaths over 5 y</th>
<th>NNS to prevent 1 death over 5 y</th>
<th>No. of false-positives per prevented death</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk-based fixed USPSTF population size</td>
<td>100</td>
<td>82,245</td>
<td>528</td>
<td>294</td>
</tr>
<tr>
<td>USPSTF</td>
<td>90</td>
<td>74,021</td>
<td>287</td>
<td>185</td>
</tr>
<tr>
<td>CMS</td>
<td>80</td>
<td>55,717</td>
<td>162</td>
<td>116</td>
</tr>
<tr>
<td></td>
<td>70</td>
<td>46,488</td>
<td>194</td>
<td>133</td>
</tr>
<tr>
<td></td>
<td>60</td>
<td>41,559</td>
<td>208</td>
<td>142</td>
</tr>
</tbody>
</table>

Ever-smokers aged 50-80 y screened, %

- 5-y lung cancer risk threshold, %
- 5-y lung cancer death risk threshold, %

No. of ever-smokers aged 50-80 y screened, millions

- USPSTF
- CMS
Risk-based strategies replace the lowest-risk USPTF-eligible smokers with higher-risk USPSTF-\textit{ineligible} smokers.

- Replacements have
  - Much higher 5-year lung cancer risk (3.2\% vs. 1.3\%)
  - Much lower NNS to prevent 1 death (226 vs. 647)

- Risk-based selection preferentially selects
  - Older (ages 70-80)
  - African-Americans
  - Current smokers
  - Low-intensity long-term current-smokers
    - 61\% of whom smoke less than \textit{half} a pack per day
    - 67\% are female; 25\% are African-American
  - High-intensity former-smokers who have quit for more than 15 years
Unforgiving Math of Screening

- 20% reduction in death applies only to:
  - Ever-smokers (~85% of lung cancer deaths)
  - 57% of US lung cancer deaths in ever-smokers from current USPSTF screening guidelines
  - Might increase to 68% under risk-based screening

- Only 10-12% of US lung-cancer deaths are realistically preventable by CT screening
  - However, this would roughly equal eliminating all US stomach cancer deaths
Achilles Heel of Precision Prevention:
Dissemination and implementation of risk-based precision prevention
How can risk-based screening happen in real-life?

• Some doubts
  – How will we collect the information?
  – What is the right risk threshold to qualify for screening?
  – What happens to those who don’t qualify but get cancer?
  – Will I get sued?

• Validated shared decision-making process
  – Validated and appropriate risk tools and quantitative decision aids
  – Validated process that accurately conveys information and leads to appropriate decision-making in light of a patient’s values

• How will this be explained?
  – Doctors, public health professionals, a trained cadre of “medical counselors”? “Screening Navigators?”
The task force does not recommend that you get screened if you are not between the ages of 55 and 80, or if you are a non-smoker, or if you are a current smoker with less than 30 pack-year of smoking or if you are a former smoker who quit for more than 15 years.

Age: 66
Gender: Male
Type of Smoker?: Current Smoker
What age did you start smoking?: 23
How many cigarettes per day do you smoke on average?: 36
Race or Ethnic Group?: White
Lung disease?: None
Family history of lung cancer?: No parent
Units?: US
Height?: 6 feet 1 inch
Weight?: 176 pounds
Education?: Vocation/technical school

Risk of dying from lung cancer within 5 years in the absence of screening: 4.29%

Click here to learn more about your results.

5-year lung cancer death risk reduction due to lung cancer screening: 0.87%
The chance of lung cancer diagnosis within 5 years in the absence of screening: 6.02%
The chance of lung cancer diagnosis within 5 years with screening: 6.77%
The chance of having a false positive result after 3 screens: 0.42%

Further Information
Learning about lung cancer and its treatment can help you prepare for your appointments, understand different types of treatment, and prevent and manage any side effects.
Lung cancer screening as a template:

Principles of precision prevention
Template for precision prevention?

- Screening general populations is hard
  - Most people at low disease risk, thus at high risk of false-positives
  - Clinical trials of screening in general populations has mixed results: low power

- Shift question from “Does screening work?” to “For whom does screening work?”

- CT lung screening model
  - When introducing a new screening program, select only those at highest risk (NLST)
  - Increased statistical power for trials (88 prevented deaths)
  - Focus on high-risk smokers has resolved an acrimonious decades-long debate about whether lung screening works
Rule-Out/Rule-In Screening: “for whom does screening work?”

• Rule-out everyone not at high risk
  – Immediately
    • Lung screening
  – Rule-out for a long time based on tests (single or sequence)
    • Cervix screening, prostate screening (?)
  – Base rule-out on: low-risk of untreatable cancer or death

• Rule-in based on triage test
  – Even HPV needs Pap and biopsy triage
  – Base rule-in on: high-risk of finding treatable disease (early stage cancer or precancer)
  – Can consider extending to those at moderate risk, if an excellent triage test exists

Castle and Katki, *Nature Reviews Clinical Oncology* (hopefully)